{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T14:16:22Z","timestamp":1768313782657,"version":"3.49.0"},"reference-count":42,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,11,26]],"date-time":"2021-11-26T00:00:00Z","timestamp":1637884800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>PD-1\/PD-L1 inhibitor immunotherapy has showed impressive activity in various cancers, especially relapsed\/refractory (r\/r) classical Hodgkin lymphoma (cHL). However, acquired resistance is inevitable for most patients. Sometimes severe side effects also lead to treatment termination. When immunotherapy failed, alternative treatment options are limited. In the past few years, we have used the anti-angiogenic agent apatinib and PD-1 inhibitor camrelizumab to treat cHL patients who failed prior immunotherapy. In this study, we analyzed the data of these patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Patients and Methods<\/jats:title><jats:p>Patients with r\/r cHL who had failed immunotherapy and subsequently received apatinib-camrelizumab (AC) combination therapy were included in this study. Patient data were collected from medical records and follow-up system. The efficacy and safety of AC therapy were analyzed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Seven patients who failed immunotherapy were identified in our database, of which five patients acquired immunotherapy resistance and two patients experienced severe side effects. They received a combination of camrelizumab (200 mg every four weeks) and apatinib (425 mg or 250 mg per day). As of the cut-off date, these patients had received a median of 4 cycles (range, 2 - 31) of treatment. Two (2\/7) patients achieved complete response, four (4\/7) partial response, and one (1\/7) stable disease. The median progression-free survival was 10.0 months (range, 2.0 \u2013 27.8). Low-dose apatinib (250 mg) plus camrelizumab was well tolerated and had no unexpected side effects. Besides, no reactive cutaneous capillary endothelial proliferation was observed in AC-treated patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Low dose apatinib plus camrelizumab might be a promising treatment option for r\/r cHL patients who have failed immunotherapy. This combination treatment is worthy of further investigation in more patients including solid cancer patients who have failed immunotherapy.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2021.727464","type":"journal-article","created":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T07:35:30Z","timestamp":1638344130000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":12,"title":["Anti-Angiogenic Agent Combined with Anti-PD-1 Immunotherapy Showed Activity in Patients With Classical Hodgkin Lymphoma Who Have Failed Immunotherapy: A Retrospective Case Report Study"],"prefix":"10.3389","volume":"12","author":[{"given":"Zheng","family":"Yan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jialin","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuna","family":"Yao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhihua","family":"Yao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haiying","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junfeng","family":"Chu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuang","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanyan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2021,11,26]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pathol.2019.09.005","article-title":"Hodgkin Lymphoma: A Review of Pathological Features and Recent Advances in Pathogenesis","volume":"52","author":"Piris","year":"2020","journal-title":"Pathology"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012556.pub2","article-title":"Nivolumab for Adults With Hodgkin's Lymphoma (a Rapid Review Using the Software RobotReviewer)","volume":"7","author":"Goldkuhle","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1411087","article-title":"PD-1 Blockade With Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma","volume":"372","author":"Ansell","year":"2015","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2018-0538","article-title":"Outcomes and Toxicities of Programmed Death-1 (PD-1) Inhibitors in Hodgkin Lymphoma Patients in the United States: A Real-World, Multicenter Retrospective Analysis","volume":"24","author":"Bair","year":"2019","journal-title":"Oncologist"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0545-2","article-title":"Treatment of Relapsed or Refractory Classical Hodgkin Lymphoma With the Anti-PD-1, Tislelizumab: Results of a Phase 2, Single-Arm, Multicenter Study","volume":"34","author":"Song","year":"2020","journal-title":"Leukemia"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2019.00387","article-title":"Safety and Efficacy of Anti-PD-1 Monoclonal Antibodies in Patients With Relapsed or Refractory Lymphoma: A Meta-Analysis of Prospective Clinic Trails","volume":"10","author":"Zhou","year":"2019","journal-title":"Front Pharmacol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.72.1316","article-title":"Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed\/Refractory Classic Hodgkin Lymphoma","volume":"35","author":"Chen","year":"2017","journal-title":"J Clin Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.67.3467","article-title":"Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure","volume":"34","author":"Armand","year":"2016","journal-title":"J Clin Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(18)30192-3","article-title":"Safety and Activity of Sintilimab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma (ORIENT-1): A Multicentre, Single-Arm, Phase 2 Trial","volume":"6","author":"Shi","year":"2019","journal-title":"Lancet Haematol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-1680","article-title":"A Single-Arm, Multicenter, Phase II Study of Camrelizumab in Relapsed or Refractory Classical Hodgkin Lymphoma","volume":"25","author":"Song","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B11","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1097\/PPO.0000000000000327","article-title":"Combinations of Bevacizumab With Cancer Immunotherapy","volume":"24","author":"Chen","year":"2018","journal-title":"Cancer J"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1215397109","article-title":"Vascular Normalizing Doses of Antiangiogenic Treatment Reprogram the Immunosuppressive Tumor Microenvironment and Enhance Immunotherapy","volume":"109","author":"Huang","year":"2012","journal-title":"Proc Natl Acad Sci U.S.A."},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms12624","article-title":"Atezolizumab in Combination With Bevacizumab Enhances Antigen-Specific T-Cell Migration in Metastatic Renal Cell Carcinoma","volume":"7","author":"Wallin","year":"2016","journal-title":"Nat Commun"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aak9679","article-title":"Combined Antiangiogenic and Anti-PD-L1 Therapy Stimulates Tumor Immunity Through HEV Formation","volume":"9","author":"Allen","year":"2017","journal-title":"Sci Transl Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-17-0640","article-title":"Low-Dose Apatinib Optimizes Tumor Microenvironment and Potentiates Antitumor Effect of PD-1\/PD-L1 Blockade in Lung Cancer","volume":"7","author":"Zhao","year":"2019","journal-title":"Cancer Immunol Res"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-12-4354","article-title":"Vascular Normalization as an Emerging Strategy to Enhance Cancer Immunotherapy","volume":"73","author":"Huang","year":"2013","journal-title":"Cancer Res"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-05-718528","article-title":"Refinement of the Lugano Classification Lymphoma Response Criteria in the Era of Immunomodulatory Therapy","volume":"128","author":"Cheson","year":"2016","journal-title":"Blood"},{"key":"B18","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.semcancer.2019.07.017","article-title":"Acquired Resistance to Cancer Immunotherapy: Role of Tumor-Mediated Immunosuppression","volume":"65","author":"Saleh","year":"2019","journal-title":"Semin Cancer Biol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3541","article-title":"Tumor Endothelium FasL Establishes a Selective Immune Barrier Promoting Tolerance in Tumors","volume":"20","author":"Motz","year":"2014","journal-title":"Nat Med"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-12-2325","article-title":"VEGFA-VEGFR Pathway Blockade Inhibits Tumor-Induced Regulatory T-Cell Proliferation in Colorectal Cancer","volume":"73","author":"Terme","year":"2013","journal-title":"Cancer Res"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-5212","article-title":"Sunitinib Reverses Type-1 Immune Suppression and Decreases T-Regulatory Cells in Renal Cell Carcinoma Patients","volume":"14","author":"Finke","year":"2008","journal-title":"Clin Cancer Res"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.178.3.1505","article-title":"Effects of Vascular Endothelial Growth Factor on the Lymphocyte-Endothelium Interactions: Identification of Caveolin-1 and Nitric Oxide as Control Points of Endothelial Cell Anergy","volume":"178","author":"Bouzin","year":"2007","journal-title":"J Immunol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2005.06.065","article-title":"Vascular Endothelial Growth Factor Impairs the Functional Ability of Dendritic Cells Through Id Pathways","volume":"334","author":"Laxmanan","year":"2005","journal-title":"Biochem Biophys Res Commun"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-07-1956","article-title":"VEGF Inhibits T-Cell Development and may Contribute to Tumor-Induced Immune Suppression","volume":"101","author":"Ohm","year":"2003","journal-title":"Blood"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V92.11.4150","article-title":"Vascular Endothelial Growth Factor Inhibits the Development of Dendritic Cells and Dramatically Affects the Differentiation of Multiple Hematopoietic Lineages","volume":"92","author":"Gabrilovich","year":"1998","journal-title":"vivo Blood"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1038\/nm1096-1096","article-title":"Production of Vascular Endothelial Growth Factor by Human Tumors Inhibits the Functional Maturation of Dendritic Cells","volume":"2","author":"Gabrilovich","year":"1996","journal-title":"Nat Med"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.598877","article-title":"Augmenting Anticancer Immunity Through Combined Targeting of Angiogenic and PD-1\/PD-L1 Pathways: Challenges and Opportunities","volume":"11","author":"Hack","year":"2020","journal-title":"Front Immunol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-021-00496-y","article-title":"Anti-Angiogenic Agents - Overcoming Tumour Endothelial Cell Anergy and Improving Immunotherapy Outcomes","volume":"18","author":"Huinen","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9030675","article-title":"Combining Immune Checkpoint Inhibitors With Anti-Angiogenic Agents","volume":"9","author":"Ciciola","year":"2020","journal-title":"J Clin Med"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01956","article-title":"Anti-Angiogenic Agents in Combination With Immune Checkpoint Inhibitors: A Promising Strategy for Cancer Treatment","volume":"11","author":"Song","year":"2020","journal-title":"Front Immunol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-14-0053","article-title":"Bevacizumab Plus Ipilimumab in Patients With Metastatic Melanoma","volume":"2","author":"Hodi","year":"2014","journal-title":"Cancer Immunol Res"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-2484","article-title":"Anti-PD-1 Antibody SHR-1210 Combined With Apatinib for Advanced Hepatocellular Carcinoma, Gastric, or Esophagogastric Junction Cancer: An Open-Label, Dose Escalation and Expansion Study","volume":"25","author":"Xu","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1816047","article-title":"Avelumab Plus Axitinib Versus Sunitinib for Advanced Renal-Cell Carcinoma","volume":"380","author":"Motzer","year":"2019","journal-title":"N Engl J Med"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)30723-8","article-title":"Atezolizumab Plus Bevacizumab Versus Sunitinib in Patients With Previously Untreated Metastatic Renal Cell Carcinoma (IMmotion151): A Multicentre, Open-Label, Phase 3, Randomised Controlled Trial","volume":"393","author":"Rini","year":"2019","journal-title":"Lancet"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2018-0876","article-title":"Sequential Therapy With Ramucirumab and\/or Checkpoint Inhibitors for non-Small-Cell Lung Cancer in Routine Practice","volume":"15","author":"Molife","year":"2019","journal-title":"Future Oncol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-2179","article-title":"Low-Dose Anti-Angiogenic Therapy Sensitizes Breast Cancer to PD-1 Blockade","volume":"26","author":"Li","year":"2020","journal-title":"Clin Cancer Res"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.01920","article-title":"Camrelizumab Plus Apatinib in Patients With Advanced Cervical Cancer (CLAP): A Multicenter, Open-Label, Single-Arm, Phase II Trial","volume":"38","author":"Lan","year":"2020","journal-title":"J Clin Oncol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-3136","article-title":"Efficacy and Biomarker Analysis of Camrelizumab in Combination With Apatinib in Patients With Advanced Nonsquamous NSCLC Previously Treated With Chemotherapy","volume":"27","author":"Zhou","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.48.8585","article-title":"Apatinib for Chemotherapy-Refractory Advanced Metastatic Gastric Cancer: Results From a Randomized, Placebo-Controlled, Parallel-Arm, Phase II Trial","volume":"31","author":"Li","year":"2013","journal-title":"J Clin Oncol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.20892\/j.issn.2095-3941.2018.0172","article-title":"Reactive Capillary Hemangiomas: A Novel Dermatologic Toxicity Following Anti-PD-1 Treatment With SHR-1210","volume":"16","author":"Chen","year":"2019","journal-title":"Cancer Biol Med"},{"key":"B41","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1080\/19420862.2018.1550321","article-title":"Anti-PD1 'SHR-1210' Aberrantly Targets Pro-Angiogenic Receptors and This Polyspecificity can be Ablated by Paratope Refinement","volume":"11","author":"Finlay","year":"2019","journal-title":"MAbs"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2019.11.011","article-title":"Overcoming Primary Resistance to PD-1 Inhibitor With Anti-PD-L1 Agent in Squamous-Cell NSCLC: Case Report","volume":"21","author":"Gelsomino","year":"2020","journal-title":"Clin Lung Cancer"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.727464\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T07:35:33Z","timestamp":1638344133000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.727464\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,26]]},"references-count":42,"alternative-id":["10.3389\/fimmu.2021.727464"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2021.727464","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,26]]},"article-number":"727464"}}